Daewoong Pharmaceutical secured an exclusive license to Innovo Therapeutics’ INV-008, an oral 15-hydroxyprostaglandin dehydrogenase inhibitor for inflammatory bowel disease, in a deal valued up to ₩662.5 billion (US$443.6 million). The transaction gives Daewoong control over development and commercialization rights under a structure that includes major milestone payments. The agreement highlights continued demand for oral, mechanism-specific IBD assets that can complement existing standards of care across Crohn’s disease and ulcerative colitis-like pathways. Innovo retains deal-related upside while leveraging Daewoong’s capacity in gastroenterology and regional development execution. The size and stage—preclinical—suggest Daewoong is underwriting a long-term clinical bet that INV-008 can translate into meaningful differentiation in later trials.